Innate Pharma (IPHA) — Tangible Net Worth Ratio
Innate Pharma (IPHA) has a Tangible Net Worth Ratio of 100.0% as of June 2025. This metric is calculated by deducting intangible assets ($0.00) from net assets ($5.14 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See net assets of Innate Pharma for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Innate Pharma Tangible Net Worth Ratio (2005–2024)
This chart shows how Innate Pharma's Tangible Net Worth Ratio has changed across 20 annual periods from 2005 to 2024. As of June 2025, the ratio stands at 100.0%, reflecting net assets of $5.14 Million with intangible assets of $0.00 USD. Also explore IPHA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Innate Pharma (2005–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Innate Pharma from 2005 to 2024, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see how much is Innate Pharma worth.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | $8.83 Million | $0.00 | $111.06 Million | ▲ +1.0 pp |
| 2023 | 99.0% | $42.90 Million | $416.00K | $175.19 Million | ▲ +77.6 pp |
| 2022 | 21.4% | $54.15 Million | $42.55 Million | $207.86 Million | ▼ -37.5 pp |
| 2021 | 58.9% | $107.44 Million | $44.19 Million | $267.50 Million | ▼ -11.5 pp |
| 2020 | 70.3% | $155.97 Million | $46.29 Million | $307.42 Million | ▲ +14.9 pp |
| 2019 | 55.4% | $217.42 Million | $96.97 Million | $401.36 Million | ▲ +5.9 pp |
| 2018 | 49.5% | $167.24 Million | $84.53 Million | $451.22 Million | ▲ +3.2 pp |
| 2017 | 46.3% | $85.96 Million | $46.19 Million | $255.02 Million | ▼ -43.2 pp |
| 2016 | 89.5% | $86.17 Million | $9.07 Million | $281.58 Million | ▲ +3.0 pp |
| 2015 | 86.5% | $72.07 Million | $9.73 Million | $305.96 Million | ▼ -6.3 pp |
| 2014 | 92.8% | $74.63 Million | $5.36 Million | $90.69 Million | ▼ -7.2 pp |
| 2013 | 100.0% | $40.29 Million | $0.00 | $55.88 Million | ▲ +0.0 pp |
| 2012 | 100.0% | $23.36 Million | $0.00 | $48.30 Million | ▲ +0.0 pp |
| 2011 | 100.0% | $26.62 Million | $0.00 | $60.11 Million | ▲ +0.0 pp |
| 2010 | 100.0% | $33.52 Million | $0.00 | $48.01 Million | ▲ +0.0 pp |
| 2009 | 100.0% | $47.12 Million | $0.00 | $64.22 Million | ▲ +0.0 pp |
| 2008 | 100.0% | $41.34 Million | $0.00 | $60.86 Million | ▲ +0.0 pp |
| 2007 | 100.0% | $49.61 Million | $0.00 | $63.15 Million | ▲ +0.0 pp |
| 2006 | 100.0% | $56.37 Million | $0.00 | $69.25 Million | ▲ +0.0 pp |
| 2005 | 100.0% | $20.07 Million | $0.00 | $24.77 Million | — |